FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042227562> ?p ?o ?g. }

• W2042227562 endingPage "3676" @default.
• W2042227562 startingPage "3668" @default.
• W2042227562 abstract "The insulin-like growth factor binding proteins (IGFBPs) are the carriers for insulin-like growth factor (IGF0-I and IGF-II. IGFBP-3 is GH-dependent and circulates associated with IGFs and an acid-labile subunit to form a 150-kilodalton (kDa) complex. In human serum, two immunoreactive molecular weight forms of IGFBP-3 have been identified. In human urine, radioimmunoassayable levels of IGFBP-3 have been detected. The objectives of this study were to characterize the molecular weight forms of IGFBP-3 in urine and serum of healthy children and adults and in children with GH deficiency (GHD), to quantify the urinary molecular weight forms of IGFBP-3, and to evaluate the relationship of these forms with GH therapy. Urine and serum were obtained from 12 prepubertal children with GHD, before and after 6 months of GH therapy, from 30 prepubertal healthy children, and from 8 healthy adults. Western immunoblotting (WIB) with IGFBP-3 antiserum (alpha IG-FBP-3g1) showed that in urine the most representative IGFBP-3 was a 17.7-kDa form. The 17.7-kDa IGFBP-3 was high in urine of healthy children compared with healthy adults and was low in children with GHD but increased after GH therapy. Urinary IGFBP-3 immunoreactive profile was determined by neutral-size exclusion chromatography, followed by IGFBP-3 RIA analysis of the fractions. Urine showed a major peak of IGFBP-3 immunoreactivity around 17 kDa. The 17-kDa urinary IGFBP-3 chromatographic peak averaged 8461 +/- 367 ng/12 h.m2 of body surface in healthy children, 3415 +/- 739 in adults (P < 0.001), 2294 +/- 354 in children with GHD before GH therapy (P < 0.001), and 7940 +/- 1874 in children with GHD after GH therapy. Urinary IGFBP-3 was also measured by RIA in unfractionated urine; healthy children showed levels significantly higher (14575 +/- 460 ng/12 h.m2) than adults (7823 +/- 1083, P < 0.001) and higher than children with GHD before GH therapy (4710 +/- 703, P < 0.001). Again, however, immunoreactive IGFBP-3 increased after GH treatment (12294 +/- 3394). In the serum of the healthy children we characterized by specific IGFBP-3 WIB analysis, a 17.7-kDa immunoreactive form of IGFBP-3 that was absent in the serum of healthy adults and low in patients with GHD, increased during GH therapy. Serum samples were subjected to neutral-size exclusion chromatography and the fractions were analyzed by WIB.(ABSTRACT TRUNCATED AT 400 WORDS)" @default.
• W2042227562 created "2016-06-24" @default.
• W2042227562 creator A5001402556 @default.
• W2042227562 creator A5023673937 @default.
• W2042227562 creator A5027990128 @default.
• W2042227562 creator A5030824019 @default.
• W2042227562 creator A5056265399 @default.
• W2042227562 creator A5056791334 @default.
• W2042227562 creator A5070247697 @default.
• W2042227562 date "1995-12-01" @default.
• W2042227562 modified "2023-09-23" @default.
• W2042227562 title "Characterization of a low molecular mass form of insulin-like growth factor binding protein-3 (17.7 kilodaltons) in urine and serum from healthy children and growth hormone (GH)-deficient patients: relationship with GH therapy." @default.
• W2042227562 cites W1482681924 @default.
• W2042227562 cites W1496795801 @default.
• W2042227562 cites W1513376696 @default.
• W2042227562 cites W1592337724 @default.
• W2042227562 cites W1974086084 @default.
• W2042227562 cites W1978041015 @default.
• W2042227562 cites W1989831107 @default.
• W2042227562 cites W1990470011 @default.
• W2042227562 cites W1995535256 @default.
• W2042227562 cites W2000330986 @default.
• W2042227562 cites W2001229549 @default.
• W2042227562 cites W2003016121 @default.
• W2042227562 cites W2004951061 @default.
• W2042227562 cites W2010245034 @default.
• W2042227562 cites W2013157204 @default.
• W2042227562 cites W2026218141 @default.
• W2042227562 cites W2030487871 @default.
• W2042227562 cites W2031909286 @default.
• W2042227562 cites W2032458902 @default.
• W2042227562 cites W2050959330 @default.
• W2042227562 cites W2061431855 @default.
• W2042227562 cites W2067114525 @default.
• W2042227562 cites W2069488741 @default.
• W2042227562 cites W2078542512 @default.
• W2042227562 cites W2108230936 @default.
• W2042227562 cites W2122634738 @default.
• W2042227562 cites W2129224839 @default.
• W2042227562 cites W2130065453 @default.
• W2042227562 cites W2150197145 @default.
• W2042227562 cites W2199609825 @default.
• W2042227562 cites W2345120190 @default.
• W2042227562 cites W2411400317 @default.
• W2042227562 cites W2461537702 @default.
• W2042227562 doi "https://doi.org/10.1210/jcem.80.12.8530618" @default.
• W2042227562 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/8530618" @default.
• W2042227562 hasPublicationYear "1995" @default.
• W2042227562 type Work @default.
• W2042227562 sameAs 2042227562 @default.
• W2042227562 citedByCount "13" @default.
• W2042227562 crossrefType "journal-article" @default.
• W2042227562 hasAuthorship W2042227562A5001402556 @default.
• W2042227562 hasAuthorship W2042227562A5023673937 @default.
• W2042227562 hasAuthorship W2042227562A5027990128 @default.
• W2042227562 hasAuthorship W2042227562A5030824019 @default.
• W2042227562 hasAuthorship W2042227562A5056265399 @default.
• W2042227562 hasAuthorship W2042227562A5056791334 @default.
• W2042227562 hasAuthorship W2042227562A5070247697 @default.
• W2042227562 hasConcept C126322002 @default.
• W2042227562 hasConcept C134018914 @default.
• W2042227562 hasConcept C170493617 @default.
• W2042227562 hasConcept C181199279 @default.
• W2042227562 hasConcept C185592680 @default.
• W2042227562 hasConcept C2775960820 @default.
• W2042227562 hasConcept C2779306644 @default.
• W2042227562 hasConcept C2780026642 @default.
• W2042227562 hasConcept C2780378035 @default.
• W2042227562 hasConcept C2780689927 @default.
• W2042227562 hasConcept C2984496839 @default.
• W2042227562 hasConcept C55493867 @default.
• W2042227562 hasConcept C58121356 @default.
• W2042227562 hasConcept C71315377 @default.
• W2042227562 hasConcept C71924100 @default.
• W2042227562 hasConcept C77411442 @default.
• W2042227562 hasConcept C86803240 @default.
• W2042227562 hasConceptScore W2042227562C126322002 @default.
• W2042227562 hasConceptScore W2042227562C134018914 @default.
• W2042227562 hasConceptScore W2042227562C170493617 @default.
• W2042227562 hasConceptScore W2042227562C181199279 @default.
• W2042227562 hasConceptScore W2042227562C185592680 @default.
• W2042227562 hasConceptScore W2042227562C2775960820 @default.
• W2042227562 hasConceptScore W2042227562C2779306644 @default.
• W2042227562 hasConceptScore W2042227562C2780026642 @default.
• W2042227562 hasConceptScore W2042227562C2780378035 @default.
• W2042227562 hasConceptScore W2042227562C2780689927 @default.
• W2042227562 hasConceptScore W2042227562C2984496839 @default.
• W2042227562 hasConceptScore W2042227562C55493867 @default.
• W2042227562 hasConceptScore W2042227562C58121356 @default.
• W2042227562 hasConceptScore W2042227562C71315377 @default.
• W2042227562 hasConceptScore W2042227562C71924100 @default.
• W2042227562 hasConceptScore W2042227562C77411442 @default.
• W2042227562 hasConceptScore W2042227562C86803240 @default.
• W2042227562 hasIssue "12" @default.
• W2042227562 hasLocation W20422275621 @default.
• W2042227562 hasLocation W20422275622 @default.
• W2042227562 hasOpenAccess W2042227562 @default.
• W2042227562 hasPrimaryLocation W20422275621 @default.

• next